Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars

医学 生物仿制药 英夫利昔单抗 炎症性肠病 溃疡性结肠炎 危险系数 阿达木单抗 内科学 置信区间 比例危险模型 医疗保健 逻辑回归 重症监护医学 疾病 克罗恩病 回顾性队列研究 梅德林 依那西普 优势比 成果研究 硫嘌呤甲基转移酶 原发性硬化性胆管炎 年轻人 不利影响 疾病严重程度 临床试验 队列研究 生物制剂 急诊医学
作者
Cristiano S Moura,Albert Etingin,Luck Lukusa,Harminder Singh,Neeraj Narula,Laura E Targownik,Yvette Leung,Petros Zezos,Beata Polewiczowska-Nowak,Waqqas Afif,Sasha Bernatsky
出处
期刊:World Journal of Gastroenterology [Baishideng Publishing Group]
卷期号:32 (9): 114580-114580
标识
DOI:10.3748/wjg.v32.i9.114580
摘要

BACKGROUND: Biologic therapies, including anti-tumor necrosis factor agents, have significantly improved the management of inflammatory bowel disease (IBD). However, their high cost can limit patient access. Biosimilars are a more affordable option than originator biologics and offer potential for improved accessibility, though real-world evidence comparing their effectiveness remains limited. AIM: To describe real-world, comparative outcomes of IBD patients taking biologics and biosimilars, focusing on remission and healthcare use. METHODS: We used data from a multicenter registry-based cohort, which includes participants from six Canadian IBD clinical centers. Adults with ulcerative colitis or Crohn's disease who initiated biosimilar, or originator formulations of infliximab or adalimumab were included. The primary outcome was clinical remission; secondary outcomes included hospitalizations and emergency department (ED) visits. Kaplan-Meier survival analyses and multivariable Cox regression models were used to assess time to these outcomes, adjusting for disease activity, treatment history, and demographic characteristics. RESULTS: A total of 258 individuals were analyzed (192 biosimilar initiators and 66 originator users). The median time to remission was similar between biosimilars (12.2 months) and originators (12.8 months). We did not detect difference in the likelihood of achieving remission when comparing biosimilar and originator treatments (adjusted hazard ratio: 1.49; 95% confidence interval: 0.96-2.32). Hospitalization and ED visit rates were also comparable. Corticosteroid use and prior hospitalizations were associated with increased hospitalization risk. CONCLUSION: This study suggests biosimilars and originators have similar remission, ED visits, and hospitalization in IBD. This reinforces confidence in their equivalence, improving access while supporting healthcare system sustainability.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被开心德地采纳,获得10
刚刚
赵晓宇完成签到,获得积分10
1秒前
沉静的安青完成签到,获得积分10
1秒前
淡定的白山完成签到,获得积分10
2秒前
2秒前
Sleven完成签到,获得积分10
3秒前
科研通AI6.2的应助被LIUDAN采纳,获得10
3秒前
活力的妙芙完成签到,获得积分10
5秒前
5秒前
传奇3的应助被腼腆的水蓝采纳,获得10
5秒前
5秒前
why完成签到 ,获得积分10
6秒前
7秒前
XX完成签到,获得积分10
7秒前
zxy完成签到,获得积分10
7秒前
CC完成签到,获得积分10
7秒前
8秒前
Wisee发布了新的文献求助10
8秒前
renbaobei完成签到 ,获得积分10
8秒前
酷波er的应助被儒雅青梦采纳,获得10
8秒前
赘婿的应助被ZRH采纳,获得10
10秒前
或无情完成签到 ,获得积分10
11秒前
11秒前
坦率涵菱发布了新的文献求助10
12秒前
朝朝完成签到,获得积分10
12秒前
畅快心情完成签到 ,获得积分10
12秒前
扶头酒发布了新的文献求助10
12秒前
火星上笑珊的应助被raise采纳,获得30
12秒前
Wisee完成签到,获得积分10
13秒前
科研通AI6.3的应助被Search瞬间采纳,获得10
13秒前
脑洞疼的应助被仔仔采纳,获得10
14秒前
14秒前
14秒前
kk完成签到 ,获得积分10
15秒前
脑洞疼的应助被ZT1采纳,获得10
15秒前
aaqaq123321发布了新的文献求助10
16秒前
16秒前
英姑的应助被Railgun采纳,获得10
18秒前
18秒前
shenkekeshen的应助被Ccc采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189302
求助须知:如何正确求助?哪些是违规求助? 9576666
关于积分的说明 21849295
捐赠科研通 7787245
什么是DOI,文献DOI怎么找? 3435521
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509